Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 12:6:33226.
doi: 10.1038/srep33226.

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis

Ting Li  1 , Li Guo  1 , Zhiwei Chen  1 , Liyang Gu  1 , Fangfang Sun  1 , Xiaoming Tan  2 , Sheng Chen  1 , Xiaodong Wang  1 , Shuang Ye  1
Affiliations

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis

Ting Li et al. Sci Rep. .

Abstract

To evaluate the efficacy of pirfenidone in patients with rapidly progressive interstitial lung disease (RPILD) related to clinically amyopathic dermatomyositis (CADM), we conducted an open-label, prospective study with matched retrospective controls. Thirty patients diagnosed with CADM-RPILD with a disease duration <6 months at Renji Hospital South Campus from June 2014 to November 2015 were prospectively enrolled and treated with pirfenidone at a target dose of 1800 mg/d in addition to conventional treatment, such as a glucocorticoid and/or other immunosuppressants. Matched patients without pirfenidone treatment (n = 27) were retrospectively selected as controls between October 2012 and September 2015. We found that the pirfenidone add-on group displayed a trend of lower mortality compared with the control group (36.7% vs 51.9%, p = 0.2226). Furthermore, the subgroup analysis indicated that the pirfenidone add-on had no impact on the survival of acute ILD patients (disease duration <3 months) (50% vs 50%, p = 0.3862); while for subacute ILD patients (disease duration 3-6 months), the pirfenidone add-on (n = 10) had a significantly higher survival rate compared with the control subgroup (n = 9) (90% vs 44.4%, p = 0.0450). Our data indicated that the pirfenidone add-on may improve the prognosis of patients with subacute ILD related to CADM.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The survival curves of the pirfenidone add-on group and the control group.
(A) Survival analysis of all patients showed that the pirfenidone add-on group had fewer deaths than the control group, but the difference was not significant. (B) The pirfenidone add-on had no impact on the survival of patients with acute ILD (disease duration <3 months). (C) The pirfenidone add-on led to a significantly higher survival rate in subacute ILD patients (disease duration 3–6 months) compared with the control subgroup.
Figure 2
Figure 2. The overall HRCT score at baseline and its changes at 6 months among survivors.
The baseline level did not significantly differ between the pirfenidone and control groups or the deceased and survivor groups.
See this image and copyright information in PMC

References

    1. Marie I. et al.. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47, 614–622 (2002). - PubMed
    1. Sontheimer R. D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositissine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46, 626–636 (2002). - PubMed
    1. Sakamoto N. et al.. Nonspecific interstitialpneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 43, 838–842 (2004). - PubMed
    1. Yokoyama T. et al.. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intensive Care Med 20, 160–163 (2005). - PubMed
    1. Ye S. et al.. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin Rheumatol 26, 1647–1654 (2007). - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources